The combination of DT2216, a Bcl-xL–targeting PROTAC, and ADZ8055 (mTORC1/2 inhibitor) synergistically killed small cell lung cancer cells but not normal cells in mice (55). This evidence concerns the gene BCL2L1 and small cell lung carcinoma.